By screening a library of a billion llama antibodies on live Ebola viruses in the Texas Biomedical Research Institute’s highest biocontainment laboratory, scientists have identified a potential weakness in the make-up of these deadly agents that can immediately yield a sensitive test.
“Detecting single viral protein components can be challenging, especially at very low levels. However, most viruses are repetitive assemblies of a few components, called antigens, with some existing as polymers which present highly ‘avid’ targets for antibodies,” said Texas Biomed virologist Andrew Hayhurst, Ph.D.
“Think of one pair of microscopic Velcro hooks where one hook is the viral antigen and the other is the antibody and it is a weak interaction. Have a thousand pairs of hooks and it makes a very powerful interaction… just like Velcro fasteners on hiking gear,” Hayhurst explained.
The screening performed by Hayhurst and assistant Laura Jo Sherwood guided the selection of llama antibodies recognizing a polymer hiding within Ebola called nucleoprotein (NP). Remarkably, each antibody could be used in its own right to form a sensitive test for the Ebola NP, whereas most tests would require two different antibodies driving up costs and characterization times.
This research -- funded by National Institutes of Health (NIH), Defense Threat Reduction Agency Basic Science Program/Office of Naval Research and the Texas Biomedical Research Institute -- was published today in the journal PLOS ONE.
”Ebola NP is rather like a cob of corn displaying hundreds of kernels linked in a repetitive polymer, giving us the perfect molecular magnet to attract llama antibodies that can be assembled into highly avid assays based on a single antibody,” Hayhurst said.
“Intriguingly, while using one antibody to polymers and aggregates has been put to use in neurodegenerative disease diagnostics for Parkinson’s, Alzheimer’s and other disorders, it has lagged behind in emerging viral diagnostics. We showcase its simplicity and effectiveness for viral threat detection here and it may well be useful for detecting other emerging viruses.”
Hayhurst’s research received NIH support from award R21 AI73394-2 and construction grant C06 RR12087.
His paper is available at 4 PM CT on April 5 at http://dx.plos.org/10.1371/journal.pone.0061232
Texas Biomed, formerly the Southwest Foundation for Biomedical Research, is one of the world's leading independent biomedical research institutions dedicated to advancing global human health through innovative biomedical research. Located on a 200-acre campus on the northwest side of San Antonio, Texas, the Institute partners with hundreds of researchers and institutions around the world, targeting advances in the fight against emerging infectious diseases, AIDS, hepatitis, malaria, parasitic infections and a host of other diseases, as well as cardiovascular conditions, diabetes, obesity, cancer, psychiatric disorders, and problems of pregnancy. For more information on Texas Biomed, go to www.TxBiomed.org, or call Joe Carey, Texas Biomed’s Vice President for Public Affairs, at 210-258-9437.